

Supplementary Materials

Synthesis and biological activity of a VHL-based PROTAC specific for p38 α

Mónica Cubillos-Rojas^{1,†}, Guillem Loren^{1,†}, Yusuf Z. Hakim¹, Xavier Verdaguer^{1,2}, Antoni Riera^{1,2,*} and Angel R. Nebreda^{1,3,*}

¹Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac 10, 08028 Barcelona, Spain


²Dept. Química Inorgànica i Orgànica, Universitat de Barcelona, Martí i Franquès 1, 08028 Barcelona, Spain.

³ICREA, Pg. Lluís Companys 23, 08010 Barcelona, Spain

Table of Contents

Figure S1. ^1H and ^{13}C NMR spectra and HPLC chromatograms of NR-11a	2
Figure S2. ^1H and ^{13}C NMR spectra and HPLC chromatograms of NR-11b	4
Figure S3. ^1H and ^{13}C NMR spectra and HPLC chromatograms of NR-11c	6
Figure S4. HPLC chromatograms of NR-11c*	8
File S1. Uncropped blots	9


Figure S1. ^1H and ^{13}C NMR spectra and HPLC chromatograms of NR-11a.



Injection date: 11/18/2020 9:25:57 PM
 Sample Name: YZH20
 Acq Operator: Analyst
 Analysis method: C:\Chem32\1\Methods\1W_4_KN50_01_GD95B10F1-5S11_T40P.M


Method Info Kinetex EVO C18 50x 4.6mm, 2.6um; Mobile phase: 10mM NH₄HCO₃ pH8 / ACN (95:5)--0.5min---(95:5)---6.5min----(0:100)---2min---(0:100) post run 1.5 min
 Sample Info: Aprox. 1 mg/mL ACN
 Walkup method: 'M1_Positive_Standard'
 Target:

VWD1 A, Wavelength=210 nm (2020_HPLC7_MS\2020-11_LCMS\2020-11-18\YZH20_126.D)



#	Meas.	Ret Peak	Width	Area	Response
1		3.538 MM	0.066	2.996	0.134
2		3.633 VB	0.044	17.127	0.765
3		4.180 VB	0.052	85.401	3.814
4		4.561 BV	0.054	5.074	0.227
5		4.646 VV	0.049	4.556	0.204
6		4.737 VV	0.074	12.600	0.563
7		4.898 VV	0.048	2.057e3	91.890
8		5.115 VB	0.074	12.315	0.550
9		5.409 BB	0.053	3.790	0.169
#		5.694 VV	0.051	15.852	0.708
#		5.752 VB	0.056	21.858	0.976

Figure S2. ^1H and ^{13}C NMR spectra and HPLC chromatograms of **NR-11b**.



Injection date: 11/18/2020 9:10:44 PM
 Sample Name: YZH19
 Acq Operator: Analyst
 Analysis method: C:\Chem32\1\Methods\1W_4_KN50_01_GD95B10F1-5S11_T40P.M

Method Info Kinetex EVO C18 50x 4.6mm, 2.6um; Mobile phase: 10mM NH4HCO3 pH8 / ACN (95:5)--0.5min---(95:5)---6.5min----(0:100)---2min---(0:100) post run 1.5 min

Sample Info: Aprox. 1 mg/mL ACN
 Walkup method: 'M1_Positive_Standard'
 Target:





Figure S3. ^1H and ^{13}C NMR spectra and HPLC chromatograms of NR-11c.



Injection date: 12/4/2020 7:51:21 PM
 Sample Name: YZH028
 Acq Operator: Analyst
 Analysis method: C:\Chem32\1\Methods\1W_4_KN50_01_GD95B10F1-5S11_T40P.M

 Method Info Kinetex EVO C18 50x 4.6mm, 2.6um; Mobile phase: 10mM NH₄HCO₃ pH8 / ACN (95:5)--0.5min---(95:5)---6.5min----(0:100)---2min---(0:100) post run 1.5 min
 Sample Info: Aprox. 1 mg/mL MeOH
 Walkup method: 'M1_Positive_Standard'
 Target:




Figure S4. HPLC chromatograms of NR-11c*.

Datafile:C:\1\DATA\2021_HPLC7-MS\2111_HPLC7-MS\2021-11-03\GL796_27.D


Injection date: 03-Nov-21 11:31:45 Flow: 1.5ml/min 1.0uL
 Sample Name: GL796 Pos: 27 351bar
 Analysis method: C:\1\Methods\1W_4_KN50_01_GD95B_L210F1-5S11_T40P.M

Kinetex EVO C18 50x 4.6mm, 2.6um; Mobile phase: 10mM NH₄HCO₃ pH8 / ACN (95:5)--0.5min---(95:5)---6.5min----(0:100)---2min----(0:100) post run 1.5 min; T^a40°C

Aprox. 1 mg/mL MeOH

Walkup method: 'M1_Positive_Standard_9min'

Target:



Signal: 2-> : VWD1 A, Wavelength=210 nm

#	Meas.	Ret. Time	Area	Area %
<hr/>				
1	0.338		15.26	1.44
2	0.417		3.14	0.30
3	3.572		1.17	0.11
4	3.630		1.26	0.12
5	4.254		10.62	1.00
6	4.334		4.83	0.46
7	4.536		2.30	0.22
8	4.751		2.56	0.24
9	4.897		1009.97	95.14
10	5.091		2.71	0.26
11	5.601		4.34	0.41
12	5.707		3.36	0.32
<hr/>				

Figure 2

9





A*MDA-MB-231*DMSO NR-11^a NR-11^b NR-11^c NR-7h**B**DMSO NR-11^a NR-11^b NR-11^c NR-7h*SAOS-2*NR-11^c NR-7h
DMSO 0.1 1 0.1 1 μ M

Figure 3

10




A**B****C**



Figure 4**A****C**


Figure 5**A**

Figure 6

13






A**B**

Figure 7**A****B****C****D**